36 results about "Dysbacterioses" patented technology

The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.

The invention relates to microbiology and medicine and can be used to prevent and treat diseases and conditions associated with disruption of normal (autochthonous) microflora (microbiota) in humans or animals. In particular, a solution for recovery or creation of the subject's microflora comprising an active component containing microorganisms isolated from the microflora of the subject or the donor, wherein the active component can be enriched with bacteriophages of said microflora and / or additional microorganisms of the microflora cultivated on a nutrient medium, while the additional microorganisms of the microflora include microorganisms of the microflora that are yet nonculturable in the absence of the host organism, is proposed. Also provided are a pharmaceutical dosage form comprising the above solution and methods for prevention or treatment of diseases and / or conditions associated with and / or accompanied by a disorder or lack of the subject's own microflora, comprising administering the solution or pharmaceutical dosage form.

The present invention provides a method for determining the likelihood of a gastrointestinal dysbiosis in an individual, the method comprising providing a test data set, wherein the test data set comprises at least one microbiota profile, the microbiota profile being a distribution of relative levels of a plurality of microorganisms or groups of microorganisms in a sample from the gastrointestinal tract of said individual and wherein each level of each microorganism or group of microorganisms is a distribution element of said test data set, to said The test data set applies at least one loading vector determined from a latent variable within a horizontal distribution of the plurality of microorganisms or groups of microorganisms in corresponding gastrointestinal samples from a plurality of normal individuals, thereby generating a first projection data set, to applying a transposed version of the at least one loading vector to the first projection data set, thereby producing a second projection data set, comparing the test data set with the second projection data set and combining the second projection data set and the difference between the corresponding distribution elements of the test data set, and combining the difference with the plurality of microorganisms or microorganisms in the corresponding gastrointestinal samples from a plurality of normal individuals and / or individuals with dysbiosis comparing the normal to dysbiotic threshold values ​​determined by the correspondence analysis of the cohorts, applying at least one eigenvalue to said first projection data set, said eigenvalues ​​being determined by said at least one loading vector, and combining each The resulting values ​​of a distribution element and combining the combined value with the flora normal to Dysbiotic thresholds are compared, wherein a microbiota profile having said combined difference or said combined result above said respective normobacterial to dysbiotic thresholds is indicative of the likelihood of dysbiosis.

The present invention provides therapeutic compositions comprising microbial populations for the prevention, treatment and alleviation of symptoms associated with dysbiosis in mammalian subjects, such as humans.